Cargando…

TP53 mutation status: emerging biomarker for precision radiation medicine?

Detalles Bibliográficos
Autores principales:	Willers, Henning, Wang, Meng, Benes, Cyril H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231449/ https://www.ncbi.nlm.nih.gov/pubmed/30460326 http://dx.doi.org/10.18632/oncoscience.468

Ejemplares similares

PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53
por: Liu, Qi, et al.
Publicado: (2018)

TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19
por: Harford, Joe B., et al.
Publicado: (2022)

Early TP53 Alterations Shape Gastric and Esophageal Cancer Development
por: Sahgal, Pranshu, et al.
Publicado: (2021)

Precision medicine for acute pancreatitis: current status and future opportunities
por: Mukherjee, Rajarshi, et al.
Publicado: (2019)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Ionizing Radiation-Induced Responses in Human Cells with Differing TP53 Status
por: Mirzayans, Razmik, et al.
Publicado: (2013)

Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet
por: Ngeow, Joanne, et al.
Publicado: (2016)

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
por: Li, Junjie, et al.
Publicado: (2021)

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

Precision cardiovascular medicine in China
por: LIU, Jie, et al.
Publicado: (2020)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Mutational status of K- ras and TP53 genes in primary sarcomas of the heart
por: Garcia, J M, et al.
Publicado: (2000)

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study
por: Syahruddin, Elisna, et al.
Publicado: (2022)

WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma
por: Zhukova, Nataliya, et al.
Publicado: (2014)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma
por: Boldrin, Elisa, et al.
Publicado: (2023)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Religious Perspectives on Precision Medicine in Singapore
por: Toh, Hui Jin, et al.
Publicado: (2021)

From Personalized Medicine to Precision Psychiatry?
por: Češková, Eva, et al.
Publicado: (2021)

Focusing on optimality for the translation of precision medicine
por: Kahkoska, Anna R., et al.
Publicado: (2022)

Precision medicine: affording the successes of science
por: Lu, Christine Y., et al.
Publicado: (2023)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

A novel strategy for precise prognosis management and treatment option in colon adenocarcinoma with TP53 mutations
por: Niu, Lei, et al.
Publicado: (2023)

TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations
por: Abedi-Ardekani, Behnoush, et al.
Publicado: (2011)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
por: Su, Mack Y., et al.
Publicado: (2016)

A role for microfluidic systems in precision medicine
por: Ayuso, Jose M., et al.
Publicado: (2022)

The role of precision medicine in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Pragmatic medicine in solid cancer: a translational alternative to precision medicine
por: Brábek, Jan, et al.
Publicado: (2016)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer
por: Langerød, A, et al.
Publicado: (2005)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and TP53 Mutation Status in Triple-Negative Cases
por: Sadzeviciene, Ieva, et al.
Publicado: (2022)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f4mcdusim3oev55kj90ml807pa